Back to top
more

Blueprint Medicines (BPMC)

(Delayed Data from NSDQ)

$104.96 USD

104.96
415,572

-1.68 (-1.58%)

Updated May 17, 2024 04:00 PM ET

After-Market: $104.88 -0.08 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BPMC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

7 items in cart

View Cart/Checkout

Blueprint Medicines Corporation [BPMC]

Reports for Purchase

Showing records 481 - 500 ( 508 total )

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 481

11/15/2016

Daily Note

Pages: 4

BLU-554 Abstract Reports Early Proof of Concept for Targeting FGFR4, Reiterate OUTPERFORM and $41 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 482

11/11/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 483

11/10/2016

Company Report

Pages: 6

Q3 Financials; Early Activity for BLU-285 in SM Patients; GIST and BLU-554 data at "Triple" Meeting

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 484

11/10/2016

Company Report

Pages: 5

Q3 Financials; Early Activity for BLU-285 in SM Patients; GIST and BLU-554 data at "Triple" Meeting

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 485

11/04/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 486

11/04/2016

Industry Report

Pages: 11

ASH 2016 Abstract Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 487

10/28/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 488

10/19/2016

Daily Note

Pages: 4

BPMC Data Preview Ahead of Preliminary Ph 1 Data Readouts

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 489

10/13/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 17

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 490

10/07/2016

Industry Report

Pages: 6

HEALTHCARE - The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 10

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 491

08/17/2016

Industry Report

Pages: 23

HEALTHCARE - 2016 PacGrow Healthcare Conference Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 492

08/17/2016

Industry Report

Pages: 23

Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 493

08/09/2016

Company Report

Pages: 6

Q2 EPS; Important Data Readouts from Three Ph 1 Studies Ahead, Reiterate OUTPERFORM and $41 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 494

05/19/2016

Industry Report

Pages: 8

ASCO 2016 Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 495

05/10/2016

Company Report

Pages: 6

Q1 EPS; BLU-554 and BLU-285 Dose Escalations Continue, Preliminary Data Updates Expected YE:16

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 496

04/21/2016

Industry Report

Pages: 8

Biotechnology AACR Roundup for Covered Companies.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 497

04/18/2016

Daily Note

Pages: 5

Presents RET Inhibitor Program BLU-667 Data at AACR, IND Submission Expected 2H:16, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 498

03/15/2016

Daily Note

Pages: 4

BPMC and Roche to Collaborate on Targeting Kinases in Immuno-Oncology

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 499

03/11/2016

Company Report

Pages: 8

Q4:15 EPS, BLU-285 Enters Second Ph 1 Study, Data-Rich 2016 Ahead, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 500

11/10/2015

Company Report

Pages: 5

3Q EPS: Systemic Mastocytosis Study Set to Initiate, New Preclinical Programs Revealed, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party